DrugPatentWatch Database Preview
Akorn Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for AKORN, and what generic alternatives to AKORN drugs are available?
AKORN has one hundred and sixty-seven approved drugs.
There is one US patent protecting AKORN drugs. There are two tentative approvals on AKORN drugs.
There are two patent family members on AKORN drugs in two countries and one hundred and eighty-eight supplementary protection certificates in fourteen countries.
Summary for Akorn
| International Patents: | 2 |
| US Patents: | 1 |
| Tradenames: | 132 |
| Ingredients: | 121 |
| NDAs: | 167 |
| Patent Litigation for Akorn: | See patent lawsuits for Akorn |
| PTAB Cases with Akorn as petitioner: | See PTAB cases with Akorn as petitioner |
Drugs and US Patents for Akorn
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Akorn | CAPASTAT SULFATE | capreomycin sulfate | INJECTABLE;INJECTION | 050095-001 | Approved Prior to Jan 1, 1982 | AP | RX | Yes | Yes | Start Trial | Start Trial | ||||
| Akorn | CALCITRIOL | calcitriol | INJECTABLE;INJECTION | 078066-001 | Jan 29, 2008 | AP | RX | No | Yes | Start Trial | Start Trial | ||||
| Akorn | DEXAMETHASONE SODIUM PHOSPHATE | dexamethasone sodium phosphate | INJECTABLE;INJECTION | 084493-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Akorn
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Akorn | ALFENTA | alfentanil hydrochloride | INJECTABLE;INJECTION | 019353-001 | Dec 29, 1986 | 4,167,574 | Start Trial |
| Akorn | SUFENTA PRESERVATIVE FREE | sufentanil citrate | INJECTABLE;INJECTION | 019050-001 | May 4, 1984 | 3,998,834 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Akorn Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 2043601 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2008014036 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Akorn Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0227494 | 95C0013 | Belgium | Start Trial | PRODUCT NAME: TIMOLOLI MALEAS EQ. TIMOLOLUM; NATIONAL REGISTRATION/DATE: 922 IS 166 F 13 19950627; FIRST REGISTRATION: SE 11901 19930910 |
| 0162036 | 2000C/032 | Belgium | Start Trial | PRODUCT NAME: LEVETIRACETAM; NAT. REGISTRATION NO/DATE: EU/1/00/146/001 20000929; FIRST REGISTRATION: CH 55297 20000329 |
| 0239710 | SPC/GB96/051 | United Kingdom | Start Trial | PRODUCT NAME: (S)-(-)-1-PROPYL-2',6'-PIPECOLOXYLIDIDE HYDROCHLORIDE MONOHYDRATE (GENERIC NAME: ROPIVACAINE MONOHYDROCHLORIDE MONOHYDRATE); REGISTERED: SE 12319 19950915; SE 12322 19950915; SE 12323 19950915; UK 0017/0375 19960517; UK 0017/0376 19960517; UK 0017/0377 19960517; UK 0017/0378 19960517 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
